Heterocyclic KRAS Inhibitors With Potency-Selectivity Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a pressing need for more effective, safer, and pharmacokinetically favorable KRAS inhibitors to target KRAS mutations in human cancers, particularly those caused by common submutations like KRAS G12D, which are prevalent in colorectal, pancreatic, and non-small cell lung cancers.
Innovation Solution
Development of heterocyclic compounds represented by Formula I-1 or Formula I-2, which act as KRAS inhibitors, offering superior activity and selectivity, and can be in the form of pharmaceutically acceptable salts, stereoisomers, deuterates, or solvates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional KRAS inhibitors are used, then some inhibitory activity is achieved, but the potency and selectivity are insufficient
Solution Approach 1:
The patent introduces specific substituent groups at defined positions on the heterocyclic core structure to enhance binding affinity and selectivity for KRAS. Different substituents (R1-R6, Cy1, Cy2) are strategically placed to optimize local interactions with the KRAS binding pocket, thereby improving potency without compromising selectivity.
Solution Approach 2:
The invention combines a core heterocyclic structure with multiple functional substituents including aryl groups, heteroaryl groups, and various substituent patterns to create a composite molecular architecture. This composite structure enables simultaneous optimization of potency, selectivity, and pharmacokinetic properties that single-structure approaches cannot achieve.
2Reliability
If KRAS inhibitors are developed to target specific mutations, then selectivity is improved, but the complexity of the compound structure increases
Solution Approach 1:
The patent divides the inhibitor molecule into distinct functional segments: a core heterocyclic structure (providing basic binding), and multiple substituent groups (R1-R6, Cy1, Cy2) that can be independently optimized for selectivity. This modular segmentation allows systematic optimization of selectivity for specific KRAS mutations while managing structural complexity through defined substitution patterns.
3Reliability
If more potent KRAS inhibitors are designed, then therapeutic efficacy is improved, but pharmacokinetic properties may be compromised
Solution Approach 1:
The patent systematically varies key molecular parameters including substituent types (R1-R6), cyclic group structures (Cy1, Cy2), and their positions to optimize the balance between potency and pharmacokinetic properties. By adjusting these parameters, the invention achieves compounds with enhanced therapeutic efficacy while maintaining acceptable absorption, distribution, metabolism, and excretion characteristics.
Data Source
AI summary
A KRAS inhibitor compound and use thereof are provided. Specifically, a heterocyclic compound represented by Formula I-1 or Formula I-2, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a deuterate thereof, or a solvate thereof are provided. The KRAS inhibitor compound exhibits a novel structure with superior activity and selectivity.